Impact of Different CRRT Modalities, Dosing Strategies, and Timing on Kidney Recovery and Prolonged Kidney Dysfunction
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Continuos renal replacement therapy.
- Who it may be relevant to
- Registry conditions: Acute Kidney Disease, Acute Kidney Injury. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Multicentric Observational Study Examining How Different CRRT Modalities, Dosing Strategies, and Timing Impact Kidney Recovery and the Development of Prolonged Kidney Dysfunction (Acute Kidney Disease) in Critically Ill Patients
Overview
KARMA study is a hospital-based research study looking at how different ways of delivering kidney support therapy (CRRT) affect patients who are critically ill. In some cases, the kidneys may temporarily stop working in very sick patients, and machines are used to filter the blood. This study is exploring whether the way the investigators use these machines - how early to start, how much treatment to give, and what type to choose - makes a difference in how well the kidneys recover. By learning from many hospitals and hundreds of patients, KARMA hopes to improve treatment choices and help patients regain their kidney function faster.
Interventions
- Device Continuos renal replacement therapy
Different modalities of CRRT: continuous veno-venous hemofiltration; continuous veno-venous hemodialysis and continuous veno-venous hemodiafiltration Different doses of CRRT: low effluent dose (\<15 ml/kg/h); medium-low effluent dose (15-25 ml/kg/h); standard effluent dose (25-30 ml/kg/h); high effluent dose (\>30 ml/kg/h
Primary outcome measures
- Percentage of patients with AKD [Time frame: 90 days]
Secondary outcome measures (1)
- Durations and severity of AKD, free days of CRRT and kidney recovery [Time frame: 90 days]
Eligibility criteria
Inclusion criteria
- Acute kidney injury
- ICU administration
Exclusion criteria
- Pre-existing CKD (GFR < 30 ml/min/1,73m2)
- Chronic dialysis-dependent end-stage renal failure
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07052617 · 02/013AG · CSOS2025